Dry Eye Disease

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

Ocular surface disease includes dry eye syndrome, blepharitis/meibomian gland dysfunction, conjunctivitis, keratitis and episcleritis/scleritis.

There is an old saying — it might even be true — that medical students who go into psychiatry do so to figure out what is wrong with them.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Jennifer Loh, MD, explains the results of the SAHARA trial comparing TearCare and Restasis for treating dry eye disease.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Marguerite B. McDonald, MD, discusses the use amniotic membranes for dry eye and persistent epithelial defects.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Douglas Katsev, MD, discusses changes he has seen in dry eye treatment with the emergence of Miebo.

M&S Technologies and Bruder Healthcare have announced the launch of the M&S Bruder Ocular Surface Analyzer, an all-in-one device that captures and provides test results for dry eye disease in as little as 15 seconds per eye.

WAILEA, Hawaii — In this Healio video perspective, Mark L. Baum, chairman and CEO at Harrow, discusses the launch of Vevye ophthalmic solution for the treatment of dry eye disease, here at Hawaiian Eye 2024.

Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.

Two pivotal phase 3 clinical trials evaluating the efficacy and safety of AR-15512 for treating the signs and symptoms of dry eye disease achieved the primary endpoint, according to a press release from Alcon.